Matthew J Ellis Selected Research

Aromatase Inhibitors

4/2023	Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer.
1/2022	Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031).
10/2021	Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.
1/2021	RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
1/2020	Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
1/2020	Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
1/2020	ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.
1/2020	Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
1/2020	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α.
10/2019	Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew J Ellis Research Topics

Disease

173	Breast Neoplasms (Breast Cancer) 01/2024 - 05/2002
120	Neoplasms (Cancer) 02/2024 - 05/2002
17	Triple Negative Breast Neoplasms 01/2023 - 01/2010
10	Pathologic Complete Response 01/2024 - 03/2009
10	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2004
7	Disease Progression 02/2024 - 07/2006
3	Carcinogenesis 11/2020 - 01/2014
3	Carcinoma (Carcinomatosis) 01/2020 - 08/2005
3	Osteoporosis 07/2017 - 04/2013
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2023 - 01/2023
2	Hypersensitivity (Allergy) 01/2021 - 01/2020
2	Squamous Cell Carcinoma of Head and Neck 01/2021 - 10/2014
2	Metabolic Bone Diseases (Osteopenia) 07/2017 - 04/2013
2	Fatigue 04/2016 - 04/2009
2	Diarrhea 04/2016 - 04/2009
1	Urinary Bladder Neoplasms (Bladder Cancer) 02/2024
1	Residual Neoplasm 01/2024

Drug/Important Bio-Agent (IBA)

73	Estrogen ReceptorsIBA 01/2024 - 08/2003
36	Aromatase InhibitorsIBA 04/2023 - 08/2003
36	Hormones (Hormone)IBA 10/2021 - 08/2003
29	Proteins (Proteins, Gene)FDA Link 01/2024 - 05/2009
26	Anastrozole (Arimidex)FDA LinkGeneric 01/2024 - 12/2006
23	Biomarkers (Surrogate Marker)IBA 01/2023 - 08/2003
21	Phenobarbital (Luminal)FDA Link 01/2024 - 08/2007
21	Estrogens (Estrogen)FDA Link 01/2021 - 08/2003
20	Letrozole (Femara)FDA LinkGeneric 04/2023 - 05/2002
18	Tamoxifen FDA LinkGeneric 01/2020 - 05/2002
17	Fulvestrant (Faslodex)FDA Link 01/2024 - 09/2009
14	DNA (Deoxyribonucleic Acid)IBA 11/2022 - 08/2007
13	RNA (Ribonucleic Acid)IBA 01/2024 - 12/2009
13	exemestane (Aromasin)FDA Link 04/2023 - 12/2006
13	Progesterone Receptors (Progesterone Receptor)IBA 01/2020 - 08/2003
12	Trastuzumab (Herceptin)FDA Link 10/2023 - 01/2004
9	Phosphotransferases (Kinase)IBA 01/2023 - 01/2004
8	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 05/2004
7	AnthracyclinesIBA 09/2023 - 10/2007
7	ErbB Receptors (EGF Receptor)IBA 08/2021 - 08/2005
7	Estradiol (Delestrogen)FDA LinkGeneric 01/2020 - 08/2009
6	ProteomeIBA 10/2023 - 12/2013
5	Messenger RNA (mRNA)IBA 02/2024 - 01/2017
5	Estrogen Receptor alphaIBA 12/2021 - 05/2004
5	Peptides (Polypeptides)IBA 03/2016 - 08/2003
5	ParaffinIBA 11/2015 - 11/2010
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2013 - 05/2004
4	taxaneIBA 09/2023 - 03/2009
4	neratinibIBA 01/2022 - 04/2009
4	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2021 - 11/2015
4	Aromatase (CYP19)IBA 01/2020 - 07/2009
4	palbociclibIBA 01/2020 - 11/2015
4	Formaldehyde (Formol)FDA Link 08/2015 - 11/2010
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023 - 12/2014
3	Tyrosine Kinase InhibitorsIBA 01/2022 - 04/2009
3	LigandsIBA 12/2021 - 09/2011
3	NVP-BKM120IBA 12/2020 - 03/2011
3	Long Noncoding RNAIBA 12/2018 - 01/2014
3	Tyrosine (L-Tyrosine)FDA Link 01/2018 - 04/2005
3	MK 2206IBA 11/2017 - 08/2013
3	Phosphatidylinositols (Phosphatidylinositol)IBA 11/2013 - 08/2004
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 08/2013 - 10/2007
3	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2011 - 05/2004
2	Interleukin-6 (Interleukin 6)IBA 02/2024 - 12/2014
2	Protein Kinases (Protein Kinase)IBA 01/2024 - 01/2005
2	Antiviral Agents (Antivirals)IBA 11/2023 - 01/2021
2	P-2 (P 2)IBA 09/2023 - 03/2009
2	APTIBA 01/2023 - 06/2015
2	Neurofibromin 1 (Neurofibromin)IBA 01/2023 - 01/2020
2	Immune Checkpoint InhibitorsIBA 12/2022 - 01/2020
2	Docetaxel (Taxotere)FDA Link 11/2022 - 08/2021
2	Carboplatin (JM8)FDA LinkGeneric 11/2022 - 08/2021
2	Everolimus FDA Link 01/2021 - 03/2011
2	CateninsIBA 01/2020 - 02/2016
2	AntigensIBA 01/2020 - 01/2018
2	human ERBB2 proteinIBA 07/2018 - 04/2012
2	MA 12 (MA12)IBA 01/2018 - 08/2012
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2018 - 08/2004
2	CytokinesIBA 01/2018 - 12/2014
2	Goserelin (Zoladex)FDA Link 11/2017 - 08/2017
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 11/2015 - 04/2012
2	AntibodiesIBA 10/2014 - 08/2011
2	Fluorouracil (Carac)FDA LinkGeneric 12/2013 - 04/2012
2	Epirubicin (Ellence)FDA LinkGeneric 12/2013 - 04/2012
2	temsirolimus FDA Link 05/2013 - 11/2012
2	TOR Serine-Threonine KinasesIBA 05/2013 - 03/2011
2	thiamine triphosphorate (TTP)IBA 11/2012 - 03/2007
2	Irinotecan (Camptosar)FDA LinkGeneric 04/2012 - 06/2011
2	Lapatinib (GW572016)FDA Link 08/2005 - 04/2005
2	LipidsIBA 08/2004 - 08/2003
1	C188-9 compoundIBA 02/2024

Therapy/Procedure

111	Therapeutics 01/2024 - 01/2003
25	Drug Therapy (Chemotherapy) 09/2023 - 01/2004
13	Neoadjuvant Therapy 01/2024 - 04/2004
13	Adjuvant Chemotherapy 01/2021 - 05/2004
3	Transplantation 11/2023 - 09/2006
3	Immunotherapy 01/2020 - 01/2017
3	Segmental Mastectomy (Lumpectomy) 06/2011 - 01/2007
2	Combination Drug Therapy (Combination Chemotherapy) 11/2022 - 04/2004
2	Precision Medicine 12/2021 - 01/2016
2	Catheters 01/2021 - 07/2013
2	Aftercare (After-Treatment) 12/2017 - 06/2011
2	Chemoprevention 11/2004 - 05/2002